HeartSciences Inc. (HSCS) - 10-Q Summary
Business Context and Reporting Period
Company: HeartSciences Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2026 (Nine months of Fiscal Year 2026)
Business Overview: A healthcare IT company developing AI-integrated electrocardiography (ECG) solutions. Key products include the MyoVista Insights platform (FDA-exempt MDDS) and the MyoVista wav ECG device (FDA 510(k) submission made in December 2025). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Nine Months Ended Jan 31, 2026 | Nine Months Ended Jan 31, 2025 |
|---|---|---|
| Revenue | $4,319 | $0 |
| Net Loss | $(6,390,971) | $(6,670,899) |
| Net Loss Per Share (Basic/Diluted) | $(2.61) | $(7.46) |
| Cash and Cash Equivalents (Ending) | $3,397,035 | $2,596,522 |
| Total Assets | $7,554,503 | $4,222,909 |
| Total Liabilities | $4,902,380 | $4,017,738 |
| Stockholders' Equity | $2,652,123 | $205,171 |
| Working Capital | $829,925 | $(1,531,754) |
Debt Profile: As of January 31, 2026, the company held approximately $3.52 million in total notes payable (current and long-term), primarily consisting of the $3.6M Streeterville Note and the FRV Note. The $2.5M Streeterville Note principal was repaid in full during the period, though accrued interest remains.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded nominal revenue of $4,319 for the nine months ended January 31, 2026, compared to zero in the prior year period. This stems from limited international distributor relationships.
- Expense Reduction: Total operating expenses decreased by approximately 9% ($553,000) year-over-year. Research and Development (R&D) expenses dropped 32% to $2.36 million, largely due to reduced cloud consulting costs and the capitalization of software development costs for the MyoVista Insights platform.
- Equity Position: Stockholders' equity increased significantly from $205,171 to $2.65 million, driven by the issuance of Series D Preferred Stock and Common Stock conversions, offsetting the accumulated deficit which grew to $82.5 million.
- Liquidity: Cash balances increased by $2.3 million to $3.4 million, primarily funded by financing activities including a $3.0 million net proceeds from a new Streeterville Note and $6.7 million from Series D Preferred Stock sales.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management believes current resources are insufficient to fund operations for the next 12 months without additional capital.
Capital Raising:
- Series D Offering: A "best efforts" offering of up to $15.0 million in Units (Preferred Stock + Warrants) is ongoing. Approximately $6.7 million has been raised to date, with $8.3 million remaining available.
- Debt Financing: In January 2026, the company issued a $3.6M unsecured promissory note to Streeterville Capital (12% interest, OID of $600k) with net proceeds of $3.0 million.
- ATM Facility: An Equity Distribution Agreement allows for up to $25.0 million in sales; approximately $4.2 million remains available.
Regulatory Status:
- MyoVista wav ECG: FDA 510(k) submission completed in December 2025. Clearance is required for U.S. commercial sales.
- AI Algorithms: Development of an impaired cardiac relaxation (e') algorithm requires additional validation to align with updated ASE guidelines.
Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing lack of proper approval processes, insufficient accounting resources, and inadequate segregation of duties. Remediation steps are underway.
Risk Factors: Risks include failure to obtain FDA clearance, inability to raise additional capital, dependence on key personnel, and potential inventory obsolescence if regulatory approval is delayed.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion given the "substantial doubt" disclosure and the burn rate of ~$5.8 million over nine months.
- Debt Covenants: Review the terms of the $3.6M Streeterville Note, specifically the redemption rights (up to $405k/month) and the 5% balance increase penalty if principal is not reduced by $1.25M within 12 months.
- FDA Timeline: Confirm the status of the 510(k) review for the MyoVista wav ECG device submitted in December 2025.
- Equity Dilution: Assess the impact of the ongoing Series D offering and potential future ATM sales on existing shareholder ownership.
- Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting to ensure future filing reliability.